論文 - 詳細
| RRC ID | 68702 |
|---|---|
| 著者 | Hamasaki T, Suzuki H, Shirohzu H, Matsumoto T, D'Alessandro-Gabazza CN, Gil-Bernabe P, Boveda-Ruiz D, Naito M, Kobayashi T, Toda M, Mizutani T, Taguchi O, Morser J, Eguchi Y, Kuroda M, Ochiya T, Hayashi H, Gabazza EC, Ohgi T. |
| タイトル | Efficacy of a novel class of RNA interference therapeutic agents. |
| ジャーナル | PLoS One |
| Abstract |
RNA interference (RNAi) is being widely used in functional gene research and is an important tool for drug discovery. However, canonical double-stranded short interfering RNAs are unstable and induce undesirable adverse effects, and thus there is no currently RNAi-based therapy in the clinic. We have developed a novel class of RNAi agents, and evaluated their effectiveness in vitro and in mouse models of acute lung injury (ALI) and pulmonary fibrosis. The novel class of RNAi agents (nkRNA®, PnkRNA™) were synthesized on solid phase as single-stranded RNAs that, following synthesis, self-anneal into a unique helical structure containing a central stem and two loops. They are resistant to degradation and suppress their target genes. nkRNA and PnkRNA directed against TGF-β1mRNA ameliorate outcomes and induce no off-target effects in three animal models of lung disease. The results of this study support the pathological relevance of TGF-β1 in lung diseases, and suggest the potential usefulness of these novel RNAi agents for therapeutic application. |
| 巻・号 | 7(8) |
| ページ | e42655 |
| 公開日 | 2012-1-1 |
| DOI | 10.1371/journal.pone.0042655 |
| PII | PONE-D-12-09301 |
| PMID | 22916145 |
| PMC | PMC3419724 |
| MeSH | Acute Lung Injury / therapy* Animals Base Sequence Bronchoalveolar Lavage Fluid Disease Models, Animal Mice Pulmonary Fibrosis / therapy* RNA Interference* RNA, Messenger / genetics RNA, Small Interfering Transforming Growth Factor beta1 / genetics |
| IF | 2.74 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 22 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 3.0 |
| リソース情報 | |
| ヒト・動物細胞 | Hepa 1-6(RCB1638) |